A simple and reproducible prognostic index in luminal ER-positive breast cancers

Background The group of estrogen receptor (ER)-positive breast cancers (both luminal-A and -B) behaves differently from the ER-negative group. At least in early follow-up, ER expression influences positively patients' prognosis. This low aggressive biology flattens out the differences of clinical management. Thus we aimed to produce a prognostic index specific for ER-positive (ERPI) cancers that could be of aid for clinical decision. Patients and methods The test set comprised 495 consecutive ER-positive breast cancers. Tumor size, number of metastatic lymph nodes and androgen receptor expression were the only independent variables related to disease-specific survival. These variables were used to create the ERPI, which was applied to the entire test set and to selected subpopulations (grade 2 (G2)-tumors, luminal-A and -B breast cancers). A series of 581 ER-positive breast cancers, collected from another hospital, was used to validate ERPI. Results In the test population, 96.9% of patients classified as ERPI-good showed a good prognosis compared with 79.6% classified as ERPI-poor (P < 0.001). ERPI effectively discriminated outcome in luminal-A and luminal-B and in G2-tumors. In the validation series, the ERPI maintained its value. Conclusion ERPI is a practical tool in refining the prediction of outcome of patients with ER-positive breast cancer.

[1]  J. Carroll,et al.  Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? , 2012, Molecular endocrinology.

[2]  Harald Frick,et al.  How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists , 2012, PloS one.

[3]  Peter A Fasching,et al.  Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment , 2011, BMC Cancer.

[4]  H. Park,et al.  Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  G. Colditz,et al.  Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women , 2011, Clinical Cancer Research.

[7]  H. Tsuda,et al.  HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens , 2010, BMC Cancer.

[8]  J. Olson,et al.  Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. , 2010, Journal of the American College of Surgeons.

[9]  R. Rosenfeld,et al.  Cases , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[10]  G. Viale,et al.  Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers , 2010, Breast Cancer Research and Treatment.

[11]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[12]  Li Jia,et al.  Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. , 2009, Cancer research.

[13]  I. Ellis,et al.  The Nottingham Prognostic Index for Invasive Carcinoma of the Breast , 2008, Pathology & Oncology Research.

[14]  R W Blamey,et al.  Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. , 2007, European journal of cancer.

[15]  A. Sapino,et al.  Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure , 2006, Virchows Archiv.

[16]  Hanina Hibshoosh,et al.  Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study , 2006, Modern Pathology.

[17]  L. Tabár,et al.  Tumor Size and Breast Cancer Detection: What Might Be the Effect of a Less Sensitive Screening Tool Than Mammography? , 2006, The breast journal.

[18]  Richard Gordon,et al.  Modeling the Effect of Tumor Size in Early Breast Cancer , 2005, Annals of surgery.

[19]  L. Goldstein,et al.  Prognostic and predictive factors in early-stage breast cancer. , 2004, The oncologist.

[20]  P. Ravdin,et al.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Sapino,et al.  What modifies the relation between tumour size and lymph node metastases in T1 breast carcinomas? , 2000, Journal of Clinical Pathology.

[22]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[23]  S. Hellman,et al.  Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W D Dupont,et al.  Histologic grading of breast carcinoma. A reproducibility study , 1994, Cancer.

[25]  C. Redmond,et al.  Pathologic findings from the national surgical adjuvant breast project protocol B‐06 10‐year pathologic and clinical prognostic discriminants , 1993, Cancer.

[26]  R. Camplejohn,et al.  Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Carter,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989, Cancer.

[28]  R. Blamey,et al.  A prognostic index in primary breast cancer. , 1982, British Journal of Cancer.

[29]  T. Jelihovsky.  Histological grading of breast carcinoma. , 1970, Australasian radiology.

[30]  I D Bross,et al.  Cancer of the breast: Size of neoplasm and prognosis , 1969, Cancer.

[31]  M. J. van de Vijver,et al.  External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement , 2011, PloS one.

[32]  M. M. M. Anees B. Chagpar MD,et al.  Lymph Node Ratio Should Be Considered for Incorporation into Staging for Breast Cancer , 2011, Annals of Surgical Oncology.

[33]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.

[34]  W. Donegan.  Tumor‐related prognostic factors for breast cancer , 1997, CA: a cancer journal for clinicians.